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Abstract
Background:  Bladder carcinoma is one of the common urological malignancies occurring
worldwide in both sexes. Use of smokeless tobacco by women is common in rural areas of
Pakistan. The clinico-pathological features of bladder carcinoma in women and association of
smokeless tobacco as a possible risk factor for bladder carcinoma has not been well described in
the literature. The objective of the study was to determine the clinico-pathological features of
histologically confirmed bladder carcinoma in women and to investigate the role of smokeless
tobacco use as a possible risk factor for its development.
Patients and methods: Of the 204 patients (160 male and 44 female M:F ratio 3.6:1) of newly
diagnosed bladder carcinoma treated at Nishtar Medical College Hospital Multan from January
1998 to December 2004, the 44 female patients were evaluated with respect to age, clinical
presentation, cystoscopic findings, histopathological reports and possible etiological factors. Data
were collected and prospectively updated at the time of discharge from hospital and during follow-
up in urology out-patient clinic.
Results: Transitional cell carcinoma accounted for all of the bladder carcinoma in women. Median
age of the patients was 55 years and 68% patients were under 60 years of age. Majority of patients
(88%) presented with hematuria. Eleven (25%) patients had superficial (pTa/pT1) while 33 (75%)
patients had muscle invasive (T2–T4) bladder carcinoma. Most (81%) superficial tumors were
papillary while muscle invasive tumors had solid configuration at cystoscopy. Of these, 21 (47%)
patients had long history of smokeless tobacco use (chewable or moist snuff).
Conclusion: Transitional cell carcinoma is the most common bladder malignancy in women in
Pakistan. Many women with bladder carcinoma had long history of use of smokeless tobacco.
Majority of patients presented with hematuria and were under 60 years of age. At the time of
diagnosis 75% women had muscle invasive bladder carcinoma. In women using smokeless tobacco,
the correlation between stage of bladder carcinoma and duration of smokeless tobacco use was
significant (p = 0.03). Further studies are needed to clarify the role of smokeless tobacco in the
development of bladder carcinoma.
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Background
Bladder carcinoma is one of the most common malignan-
cies occurring worldwide. It is seen mainly in men. The
incidence in women is approximately 3 to 4 times lower
than in men but it seems to be rising [1]. Bladder cancer
has been associated pathogenetically with many etiologi-
cal factors which include occupational exposure to certain
chemicals e.g. aniline dyes, cigarette smoking, viral agents,
bacterial and parasitic infections, cystolithiasis, cyclo-
phosphamide therapy and pelvic irradiation [2].
The initial clinical evaluation consists of history and phys-
ical examination, upper tract studies (IVU +/- Ultrasonog-
raphy) and urine cytology followed by cystoscopy and
transurethral resection of bladder tumor.
Most cases of the bladder carcinoma are superficial at the
time of diagnosis (stage Ta-T1). The recurrence of the
superficial tumors can be as high as 70%, with 10–15%
progressing to muscle invasive disease [3].
Despite the fact that bladder carcinoma is among one of
the common malignancies in women worldwide, the eti-
ological and clinico-pathological aspects of bladder carci-
noma are not well described in the literature. In contrast
to many Western countries use of smokeless tobacco in
women is quite common in rural areas of Pakistan. The
primary objective of the present study was to determine
the clinico-pathological features of histologically con-
firmed bladder carcinoma in women and the secondary
objective was to investigate smokeless tobacco use as a
possible risk factor for it.
Patients and methods
Two hundreds and four patients of newly diagnosed blad-
der carcinoma were treated in the department of urology,
Nishtar Hospital Multan, Pakistan from Jan 1998 to
December 2004. Age, clinical presentation, cystoscopic
findings and histopathological reports, and possible etio-
logical risk factors of bladder carcinoma in women were
studied prospectively.
After initial clinical evaluation and routine hematological,
biochemical and radiological investigations all patients
underwent cystoscopy and transurethral resection of blad-
der tumor (TURBT). All women were treated as inpatients
and none of the patients had undergone TURBT previ-
ously. In all cases complete removal of papillary tumor
was performed. In cases of solid muscle invasive tumors
either complete resection or generous debulking of exo-
phytic tumor was carried out. Cystoscopic tumor configu-
ration was compared with the histopathological reports.
Data were collected and prospectively updated at the time
of discharge from hospital and during follow-up in urol-
ogy out-patient clinic.
Detailed information about the smoking habits, use of
smokeless tobacco (chewable or snuff), use of hair color-
ing dyes, occupational exposure to chemicals was
obtained from all patient. Many of the women had long
history of smokeless tobacco use, its duration and fre-
quency was inquired from such patients. Possible effect of
smokeless tobacco on the depth (T category) of bladder
carcinoma in such patients was studied and compared
with patients not using any form of tobacco.
Results
Two hundred and four patients (160 male and 44 female
with male female ratio 3.6:1) were treated. The age of the
female patients ranged from 26–80 years (median age 55
years). Hematuria was the predominant symptom in 39
(88.6%) patients at the time of presentation. A total of 21
patients had painless and 18 patients had painful hema-
turia. Four patients presented with various urinary com-
plaints but had no hematuria. In one patient the bladder
tumor was incidentally detected on ultrasonography per-
formed for some other complaints. The mean duration of
symptoms was 4 months (range 2 weeks to 16 years)
At presentation mean hemoglobin concentration was 9.5
grams/dL (range 3.9 grams to 13.3 grams). Six (13.6%)
patients had renal insufficiency (serum creatinine > 1.5
mg %) secondary to ureteric obstruction from bladder car-
cinoma. All patients had transitional cell carcinoma.
Eleven (25%) patients had non-invasive superficial (i.e.
pTa or pT1) transitional cell carcinoma while 33 (75%)
patients had muscle invasive (T2–T4) transitional cell car-
cinoma. The median duration of symptoms for noninva-
sive transitional cell carcinoma was 1.5 years (range 2
weeks to 16 years) and it was 4 months (range 1 month to
2 years) for muscle invasive carcinoma.
Most superficial tumors had papillary and muscle invasive
tumors had solid configuration at cystoscopy. Average size
of the superficial and invasive tumor was 4 cm (range 1–
8 cm) and 3.8 cm (range 2–8 cm) respectively. Of the
superficial tumors 2 (18%) were pTa and 9 (82%) were
pT1 tumors. Three pT1 tumors were grade I and five
patients had grade II tumors. One patient had high-grade
pT1 grade III carcinoma. There was no carcinoma in situ
although no random biopsies were taken.
Of the muscle invasive tumors T2, T3 and T4 tumors were
present in 14, 15 and 4 patients respectively. Thirteen
patients with muscle invasive disease had histological
grade III carcinoma while twenty patients had grade II car-
cinoma. None of the patients had GI tumor. Two patients
had marked iliac and para-aortic lymphadenopathy while
one patient had iliac and para-aortic lymphadenopathy
and liver metastases at the time of diagnosis.World Journal of Surgical Oncology 2005, 3:53 http://www.wjso.com/content/3/1/53
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All females were non smokers but 21 (47%) patients had
long history of smokeless tobacco use (moist snuff
(niswar) 12 patients, chewable tobacco (beera) in 5
patients and chewed tobacco with betel nuts (pan) in 4
patients most of these were currently using these sub-
stances at the time of presentation. All such patients came
from rural areas of Punjab and were uneducated. Patients
were asked whether they were using smokeless tobacco 5
or less than 5 times/day or greater than 5 times /day.
By employing cross tabulation (table 1) of duration of
smokeless tobacco use and depth (T category) of bladder
carcinoma, it appears that majority of such patients had
muscle invasive carcinoma at presentation and about
60% of patients have been using smokeless tobacco
between 20–30 years. The correlation between the depth
of bladder carcinoma and duration of smokeless tobacco
use was 0.473 which is statistically significant (p = 0.03).
However correlation between bladder carcinoma and
intensity of exposure to smokeless tobacco was 0.24
which showed a weak relationship. This might be due to
the fact that the patients were using different quantities of
smokeless tobacco from different sources.
We applied two independent sample t test for the compar-
ison of depth of invasion. (by using T category of TNM
stage) of bladder carcinoma in users and nonusers of
smokeless tobacco. Patients using smokeless tobacco were
assigned to group I and nonusers to group II (i.e. control
group). The mean depth of bladder carcinoma in group I
and II was 2.43 (standard deviation 0.93) and 2.13
(standard deviation 0.97) respectively. The datum shows
that the carcinoma are of higher depth (T category) in
group I, however the t value for the difference between the
two groups is 1.04 which indicated that this difference
was not statistically significant. Larger studies should be
able to clarify the role of smokeless tobacco as an etiolog-
ical risk-factor for bladder carcinoma.
Discussion
Bladder carcinoma is the fourth most common cancer in
men in the USA and eight most common cancers in
women [4]. In Pakistan bladder carcinoma is one of the
top ten malignancies in men and most common urologi-
cal malignancy in both sexes [5]. Bladder cancer predom-
inantly affects male, with a sex ratio of 3:1, suggesting sex-
linked etiological factors [6]. In the present study the male
female sex ratio was 3.6: 1. In women bladder cancer usu-
ally occurs above the age of 60 years [7], in the present
study however the median age was 55 years and 68%
women were less than 60 years of age.
A neoplastic change in the urothelium is a multi-step phe-
nomenon [8]. The exact genetic events leading to this
multi-step transformation are unknown, but they are
likely to be multiple and may involve the activation of
oncogenes and inactivation or loss of tumor suppression
genes [9]
Cigarette smoking is the single most important cause of
bladder carcinoma. Smokers have up to four fold higher
incidence of bladder cancer than do people who never
smoked [10]. The risk correlates with the number of ciga-
rettes smoked, the duration of smoking and the degree of
inhalation of smoke. Causative agents in cigarette smoke
are thought to be alpha and beta naphthylamine, which
are secreted in to urine of smokers [11]. When compared
by number of cigarettes are smoked, the risk of bladder
carcinoma may be higher in women than men [12] Ciga-
rette smoking accounts for 50% and 31% of bladder can-
cers in men and women respectively [13]. Other forms of
tobacco use are associated with only a slightly higher risk
of bladder cancer [10].
In Pakistan 36% of men and 9% women are smokers [14].
Tobacco is also used in other forms such as hookah
(hubble bubble), moist snuff used as an oral dip (niswar),
chewed with betel nuts (pan) and smoking of rolled dry
leaves containing tobacco (beedi). The most common
form of tobacco use in women in rural Pakistan is
Table 1: Depth (T category) of bladder carcinoma and duration of smokeless tobacco use
Duration of smokeless tobacco use
1–10 years 11–20 years 21–30 years 31–40 years Total
T1 (pTa/pT1) 121 4
T2 33 6
T3 2619
T4 22
Total 171 2 12 1World Journal of Surgical Oncology 2005, 3:53 http://www.wjso.com/content/3/1/53
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chewing tobacco and snuff but because of cultural prohi-
bitions women may under report use of tobacco [15]. In
the present study none of the women were smokers but
47% women had history of intake of moist snuff (niswar)
or chewable tobacco (beera and pan) and all came from
the rural areas. The median duration of use of such
tobacco products was 27 years (range 10–40 years).
Chewing tobacco and snuff contains many carcinogens.
The most harmful carcinogens in smokeless tobacco are
the tobacco specific nitrosamines (TSNA). They are
formed during the growing, curing, fermenting and aging
of tobacco [16]. Long term use of snuff can lead to a
number of adverse health affects including oral cancer,
cardiovascular diseases and gingival diseases [17]. How-
ever the etiological relationship between smokeless
tobacco and bladder carcinoma has not been well eluci-
dated in the literature and there is still no agreement
among the researchers whether smokeless tobacco use
enhances the risk of bladder cancer. Some studies
reported increased risk of bladder cancer in smokeless
tobacco users [18,19] while others [12] could find no such
risk in smokeless tobacco users. All studies included
smaller number of bladder cancer patients using smoke-
less tobacco.
In the present study 47% women had long history of
smokeless tobacco use and the correlation between the
stage of bladder carcinoma and duration of smokeless
tobacco was significant (p = 0.03). However, there was
weak correlation between bladder carcinoma and inten-
sity of exposure to smokeless tobacco. This might be due
to the fact that women were using different quantities and
forms of the locally available smokeless tobacco. As there
is long latent period between exposure to carcinogens and
the development of bladder carcinoma, it is possible that
prolong use of smokeless tobacco among women in the
present study was either the etiological factor or had mod-
ifying effect on its development. However further studies
are required to clarify the role of smokeless tobacco in the
development of bladder carcinoma.
In the USA percentage of bladder cancers attributed to
occupational exposure is 21% for men and 11% for
women [1]. None of the women in present study were
exposed to occupational chemicals.
Majority of the patients with bladder carcinoma present
with either hematuria or irritative voiding symptoms [20].
In the present study majority of women (88%) presented
with hematuria while some (9 %) had variable urinary
symptoms. In one patient the tumor was incidentally
detected on ultrasonography.
In the developed world transitional cell carcinoma is
reported for most bladder carcinoma. About 25% of
newly diagnosed cancers are muscle invasive (T2–T4); the
rest are superficial (70%), classified as limited to the
mucosa (pTa), lamina propria (pT1) or being in situ (Tis
5%) [21].
In the present study all patients had transitional cell carci-
noma. Some authors have reported that bladder cancer is
of a higher stage at initial diagnosis in women [1]. In the
present study 25% patients had superficial (pTa/pT1) and
75% patients had muscle invasive balder carcinoma. In a
report from another Pakistani centre 97% of bladder car-
cinomas were muscle invasive [22] but clinico-pathologi-
cal differences in women with bladder cancer were not
separately reported. This high percentage of muscle inva-
sive bladder carcinoma in Pakistan is in contrast to all
other studies from USA and Europe.
Overall survival in patients with superficial disease is
excellent. However 60%-70% of superficial tumors recur
and 5% of pTa and 25% of pT1 tumors progress to inva-
sive disease [21]. For recurrence risk, multiplicity of the
tumor is the most important followed by recurrence rate,
volume of the tumor, grade and T category. For progres-
sion the most important factor is the histological grade
and the T category T1 GIII tumors carry poor prognosis
and up to 50% progress to invasive disease [23].
Patients with tumors just invading detrusor muscles have
a 50% five years survival whereas those whose tumors
have invaded beyond the detrusor muscle have a 10% five
years. At the time of diagnosis 50% of muscle invasive
tumors have occult metastases which will manifest them-
selves clinically within 12 months; few such patients sur-
vive beyond two years [21]. In the present study two
patients had marked iliac and para-aortic lymphadenopa-
thy while one patient had iliac and para-aortic lymphade-
nopathy and liver metastases at the time of diagnosis.
Conclusion
Transitional cell carcinoma is the most common bladder
malignancy in women in Pakistan. Most women with
bladder carcinoma have long history of use of smokeless
tobacco. At the time of diagnosis 75% women have mus-
cle invasive bladder carcinoma. In women using smoke-
less tobacco, there is significant correlation between stage
of bladder carcinoma and duration of smokeless tobacco
use. Further studies are required to clarify the role of
smokeless tobacco in the development of bladder
carcinoma.
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